Analysts hold a pessimistic view on Enanta Pharmaceuticals a...
Analysts hold a pessimistic view on Enanta Pharmaceuticals after its earnings shortfall. The consensus price target dropped significantly, suggesting lower earnings per share are a key indicator for the company's valuation. The company's long-term prospects are deemed more crucial than next year's earnings.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000194a82c59b4e97.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment